CONSOLIDATED ENTITIES AND ACQUISITIONS - Theravance Respiratory Company, LLC (Details) - USD ($) $ in Thousands		12 Months Ended
	Jul. 20, 2022	Dec. 31, 2023	Dec. 31, 2022		Dec. 31, 2021
Assets
Cash and cash equivalents		$ 193,513	$ 291,049
Prepaid expenses and other current assets		21,630	29,559
Equity and long-term investments		444,432	363,859
Total assets		1,243,507	1,231,497
Liabilities and Stockholders Equity
Current liabilities		38,134	134,968
Total liabilities and stockholders' equity		1,243,507	1,231,497
Income statements
Total net revenue		310,463	331,339		$ 391,866
Other income, net		(4,969)	(3,373)		(3,626)
Income tax expense, net		14,376	66,687		76,439
Net income		179,722	220,262		368,837
Royalty revenue
Income statements
Total net revenue		238,846	$ 311,645		391,866
Theravance Respiratory Company, LLC
CONSOLIDATED ENTITIES
Ownership interest in LLC			15.00%
Proceeds from sale of economic interest under Equity Purchase Agreement	$ 277,500
Contingent sales based milestone payment	50,000
Cash distribution	4,400
Total carrying value of investments	$ 39,400
Income statements
Operating expenses			$ (332)	[1]	(3,956)
Income from operations			71,697	[1]	122,732
Other income, net			10	[1]	0
Realized loss			(39,386)	[1]	0
Income tax expense, net			1	[1]	0
Changes in fair values of equity and long-term investments			(8,884)	[1]	(1,541)
Net income			23,438	[1]	121,191
Theravance Respiratory Company, LLC | Royalty revenue
Income statements
Total net revenue			72,029	[1]	126,688
ISP Fund LP
Assets
Total assets		311,800	320,600
Income statements
Changes in fair values of equity and long-term investments		$ 2,400	$ 6,800		$ 10,500

[1] (1) The year ended December 31, 2022 represents the period from January 1, 2022 to July 20, 2022, the date of the sale of our ownership interest in TRC.